PAR-23-159: Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
Closed
This grant is closed. A newer notice from the same program is open now: Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) (PAR-25-450). Status: Due dates in the notice, expires July 20, 2028. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $275,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 17, 2024.
From the official notice on Grants.gov, last changed April 13, 2023. Checked November 7, 2026.
- Award ceiling$275,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsNot allowed
- Funded byNCATS, NICHD
- Median yearly award$415,245
- Typical project length2 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under PAR-23-159 were run by National Center for Advancing Translational Sciences (NCATS, 8 projects) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-23-159 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-450 | September 22, 2025 | Due dates in the notice, expires July 20, 2028 | Open |
| PAR-22-101 | February 3, 2022 | Closed April 13, 2023 | Closed |
Key dates
| Posted | April 13, 2023 |
|---|---|
| Deadline | October 17, 2024 |
| Archived by Grants.gov | November 22, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $415,245; it allows up to $275,000 per award.
- Most of the money in the 2 programs behind this notice (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Funded under PAR-23-159 so far
NIH funded 10 projects under PAR-23-159 in fiscal 2024 to 2025, at 8 institutions. The median yearly award was $415,245.
Who has won Child Health and Human Development Extramural Research grants before
From fiscal 2021 to 2025, Child Health and Human Development Extramural Research (93.865) awarded $6.0 billion across 6,026 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 167 | $178 million |
| The Johns Hopkins University | Maryland | 133 | $146 million |
| University of Washington | Washington | 114 | $131 million |
| Baylor College of Medicine | Texas | 116 | $124 million |
| The Leland Stanford Junior University | California | 104 | $116 million |
Who has won National Center for Advancing Translational Sciences grants before
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 15 | $95.3 million |
| Vanderbilt University Medical Center | Tennessee | 10 | $94.6 million |
| Duke University | North Carolina | 11 | $88.9 million |
| University of North Carolina at Chapel Hill | North Carolina | 16 | $74.5 million |
| The Johns Hopkins University | Maryland | 20 | $70.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-450, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-23-159 still open?
No. It closed on October 17, 2024. A newer notice is open: PAR-25-450, due dates in the notice, expires July 20, 2028.
Who can apply for Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)?
Closed October 17, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $275,000 each.
Who has been funded under PAR-23-159?
NIH RePORTER lists 10 projects funded under PAR-23-159 in fiscal 2024 to 2025, at 8 institutions. The most were at University of California, San Diego, Children's Hosp of Philadelphia, University of Pennsylvania.
Who has won National Center for Advancing Translational Sciences grants before?
The largest recipients over five fiscal years were University of Pittsburgh - of the Commonwealth System of Higher Education, Vanderbilt University Medical Center, Duke University. The program made 867 awards worth $3.1 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)